Advertisement

Topics

Pfizer's Herceptin Biosimilar Shows No Clinically Meaningful Differences

07:00 EDT 12 Sep 2017 | PharmPro

Pfizer presents positive pivotal data for PF-05280014, an investigational biosimilar to Herceptin (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress. Marketing applications accepted for review by the FDA and EMA.
Contributed Author: 
Pfizer Inc.

Original Article: Pfizer's Herceptin Biosimilar Shows No Clinically Meaningful Differences

NEXT ARTICLE

More From BioPortfolio on "Pfizer's Herceptin Biosimilar Shows No Clinically Meaningful Differences"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...